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A B S T R A C T
Glioblastoma (GBM) is the most common brain tumor in adults and the mesenchymal GBM subtype was
reported to be the most malignant, presenting severe hypoxia and necrosis. Here, we investigated the
possible role of a hypoxic microenvironment for inducing a mesenchymal and invasive phenotype. The
exposure of non-mesenchymal SNB75 and U87 cells to hypoxia induced a strong change in cell mor-
phology that was accompanied by enhanced invasive capacity and the acquisition of mesenchymal marker
expression. Further analyses showed the induction of HIF1α and HIF2α by hypoxia and exposure to digoxin,
a cardiac glycoside known to inhibit HIF1/2 expression, was able to prevent hypoxia-induced mesen-
chymal transition. ShRNA-mediated knockdown of HIF1α, and not HIF2α, prevented this transition, as
well as the knockdown of the EMT transcription factor ZEB1. We provide further evidence for a hypoxia-
induced mesenchymal shift in GBM primary material by showing co-localization of GLUT1, ZEB1 and the
mesenchymal marker YKL40 in hypoxic regions of the tumor. Collectively, our results identify a HIF1α–
ZEB1 signaling axis that promotes hypoxia induced mesenchymal shift and invasion in GBM in a cell line
dependent fashion.
© 2015 Elsevier Ireland Ltd. All rights reserved.
Introduction
Glioblastoma (GBM) is the most aggressive brain tumor, and
despite multimodal treatment with surgery, radiation and chemo-
therapy patients generally show incurable relapse of the disease [1].
The median survival time of patients with GBM is <16 months even
after optimal treatment [2]. Recent advancements in genomic se-
quencing and transcriptome analysis have stratiﬁed GBM into
different molecular subtypes [3,4], of which themesenchymal (MES)
and proneural (PN) subtypes appear to be the most pronounced [5].
A mesenchymal phenotype in GBM has been associated with tumor
aggressiveness and elevated invasive potential [4,6]. Interestingly,
high levels of tumor necrosis were observed in tumors of patients
having amesenchymal subtype [4]. Furthermore, a recent study dem-
onstrated that GBM cells surrounding necrotic zones and suffering
from hypoxic conditions express high levels of the mesenchymal
transcription factors C/EBP-β and C/EBP-δ and, in addition, the ex-
pression of these transcription factors was associated with a poor
prognosis [7].
GBMs generally display rapid cell proliferation and inadequate
vascularization leading frequently to tumor areas with insuﬃ-
cient oxygen supply [8]. This chronic exposure to extremely low
levels of oxygen frequently produces necrotic zones surrounded by
densely packed hypoxic tumor cells. These so-called pseudo-
palisading GBM cells were shown to express hypoxia-regulated genes
that control crucial processes associated with tumor aggressive-
ness such as angiogenesis, extracellular matrix degradation, and
invasive behavior [7,9]. Hypoxia is also a well-recognized compo-
nent of the tumor microenvironment and has been linked to poor
patient outcome and resistance to therapies in different cancer types
[10–15].
The cellular responses to hypoxia are generally mediated by the
hypoxia-inducible factor (HIF) family of transcription factors [16,17].
HIFs function as heterodimers composed of an oxygen-sensitive HIFα
subunit and a constitutively expressed HIFβ subunit. Under normoxic
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conditions HIFα is subjected to proteasomal degradation as a
result of ubiquitination by the von Hippel–Lindau (vHL) tumor-
suppressor gene product. Under hypoxic conditions, however, the
interaction between HIFα and vHL is abrogated and as a conse-
quence of this the HIFα subunit is stabilized, thereby allowing
dimerization with HIFβ and subsequent binding to hypoxia-
responsive elements (HREs) in the promoters of hypoxia-regulated
genes. In this way the transcription of hundreds of downstream genes
are regulated that can modulate cell survival, motility, metabo-
lism and angiogenesis in order to restore oxygen homeostasis
[16,18,19]. Two HIFα subunits, HIF1α and HIF2α, are structurally
similar in their DNA binding and dimerization domains, but show
differences in their transactivation domain. HIF1α and HIF2α are
known to have non-overlapping biological roles each having unique
target genes and requiring different levels of oxygen for activation
[20].
Hypoxia is a well-known inducer of the epithelial to mesenchy-
mal transition (EMT) program in epithelial cancers like pancreatic
ductal adenocarcinoma [21], hepatocellular carcinoma [22], ovarian
carcinoma [23] and lung cancer [24]. EMT can contribute toward
the invasion–metastasis cascade by inducing mesenchymal prop-
erties in tumor cells, including anoikis resistance and the ability to
migrate and invade surrounding tissues [25]. Although the inva-
sive phenotype of GBM is one of the major reasons for the poor
prognosis associated with this disease, the involvement of hypoxia-
induced mesenchymal transition has been hardly explored [26,27].
In the present study we examined whether hypoxia can induce
a mesenchymal shift in GBM cells and explored the consequences
for their invasive behavior and the underlying molecular mecha-
nisms involved. We provide evidence for the concept that GBM cells
undergo a mesenchymal transition in necrotic areas of the tumor
thus facilitating the invasive behavior of the tumor.
Materials and methods
Cell lines and treatments
The human GBM cell lines U87 and SNB75 were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA) and U251 was obtained from the
CLS Cell Lines Service GmbH (Eppelheim, Germany). U87 was cultured on cell culture
ﬂasks pre-coated with 1% gelatine from porcine skin (Sigma-Aldrich Chemie B.V.,
Zwijndrecht, The Netherlands) in Dulbecco’s modiﬁed Eagle’s Medium high glucose
(DMEM-Hg) (Gibco Life Technologies, Bleiswijk, The Netherlands) medium supple-
mented with 10% FCS and 1% penicillin(pen)/streptomycin(strep) (Gibco Life
Technologies). SNB75 and U251 did not require gelatin coating of the ﬂasks. Cell lines
were maintained at 37 °C in a humidiﬁed atmosphere with 5% CO2. When indi-
cated, cells were treated with the HIF1α and HIF2α inhibitor digoxin (AxonMedchem,
Groningen, The Netherlands). The inhibitor was added at a concentration of 150 nM
2 hrs prior to exposing the cells to hypoxia.
For hypoxia treatment, cells were ﬁrst maintained in the regular normoxic in-
cubator for around 12 h until the cells attached to the ﬂasks. Following this the ﬂasks
were transferred to the tri-gas incubator (Sanyo MCO 18M, from Sanyo E&E Europe
BV, Etten-Leur, The Netherlands) ﬁlled with 1% O2, 5% CO2 and 94% N2, at 98% hu-
midity and 37 °C.
Western blotting
Preparation of protein lysates and Western blotting was carried out as de-
scribed previously [28]. The membranes were probed with antibodies against HIF1α
[1:1000, abcam (ab2185), Cambridge, UK], HIF2α [1:500, abcam (ab199)], SNAI1/
SNAIL1 [1:500, Santa Cruz Biotechnology Inc (sc-10433), Santa Cruz, CA, USA], SLUG/
SNAIL2 [1:500, Santa Cruz Biotechnology Inc (sc-166476)], ZEB1 [1:500, Santa Cruz
Biotechnology Inc (sc-81428)], Twist antibody [1:1000 abcam, (ab50581)], Fibronectin
[1:2500, BD Transduction Laboratories (610077), Franklin Lakes, NJ, USA], COL5A1
[1:2000, Santa Cruz Biotechnology, Inc (sc-20648)]. β-actin [1:10,000, MP Biomedicals
(08691001), Duiven, The Netherlands] expression levels served as loading control.
After incubation membranes were washed with TBST (20 mmol/l Tris–HCL (pH 8.0),
137 mmol/l NaCl and 0.1% Tween-20), and reprobed with appropriate HRP-
conjugated secondary antibodies, anti-mouse immunoglobulin G (IgG), anti-rabbit
IgG or anti-goat IgG) (Dako, Glostrup, Denmark) for 1 h at RT. Proteins were visu-
alized by chemiluminescence using BM chemiluminescence detection kit (Roche
Applied Science, Almere, The Netherlands).
Immunoﬂuorescence microscopy
Cells cultured on poly L lysine (Sigma-Aldrich)-coated cover slips were ﬁxed for
10 min using 4% formaldehyde. After 3 times washing with cold PBS, cells were
permeabilized with 0.1% Triton (Sigma-Aldrich) in PBS, washed again with PBS fol-
lowed by a blocking step for 1 h with PBS + 0.1% Tween-20 (Sigma-Aldrich), 2% BSA
(PAA Laboratories GmbH, Colbe, Germany) and 1:50 dilution of normal goat serum
(Dako). Subsequently, cells were incubated with the indicated primary antibodies
at room temperature for 1.5 h. Primary antibodies used: puriﬁed mouse Fibronectin
[1:100, BD Transduction Laboratories (610077)], COL5A1 [1:200, Santa Cruz Bio-
technology (sc-20648)], HIF1α [1:1000, abcam (ab2185)], HIF2α [1:100, abcam
(ab199)], ZEB1 [1:50, Santa Cruz Biotechnology Inc (sc-10572)]. After 4-times washing
with PBS, slides were incubated for 1 h with the appropriate secondary antibod-
ies: goat anti-Mouse Alexa 488 (1:200, Life Technologies), Donkey anti-goat Alexa
488 (1:200) or Goat anti-Rabbit IgG Antibody, Cy3 conjugate (1:400, Millipore (AP132
C)). Hoechst (Sigma H6024) staining was performed for 5 min followed by mount-
ing the coverslips with Kaisers glycerin (Merck, Darmstadt, Germany). Cells were
examined by ﬂuorescent microscopy (Leica DM6000, Leica Microsystems GmbH,
Mannheim, Germany) and images were captured using Leica DFC360 FX camera.
Transwell-invasion assay
The invasion potential was determined on Gelatin-coated Transwell inserts with
8 μm pore size (Becton Dickinson B.V., Breda, The Netherlands). For this, cells were
trypsinized and resuspended in 0.1% FCS containing medium. 150 μl of a cell sus-
pension containing 5 × 104 cells was added to the Transwell in triplicates per condition.
10% FCS or 0.1% FCS was added to the lower wells as chemoattractants. Cells that
migrated/invaded and appeared on the bottom surface of the Transwell insert mem-
brane were ﬁxed with 75% methanol/25% acidic acid for 20 min and stained with
0.25% Coomassie blue in 45% methanol/10% acetic acid followed by washing with
demi water. The membranes were subsequently cut out and mounted on micro-
scopic slides for quantiﬁcation. Representative pictures of the membranes with cells
were acquired at 5× magniﬁcation and the total number of cells on ﬁfty individual
ﬁelds per membrane was counted; average numbers and standard deviation of in-
vading cells for every condition were calculated.
Wound healing assay
The migratory capacity of cells was determined by wound healing assays. Brieﬂy,
2 × 105 cells were seeded on poly-L-Lysine (Sigma-Aldrich) coated 6 well plates in
culture medium; upon conﬂuency a scratch was made using a P10 pipette tip. The
rate of wound closure was monitored at different time points under a microscope.
Short interfering RNA silencing
Validated Stealth RNAi (OriGene SR304746, Rockville, MD, USA) speciﬁc for ZEB1
was transfected into U87 cells by using Lipofectamine RNAiMAX (Invitrogen, Leek,
The Netherlands) according to the manufacturer’s protocol. Trilencer-27 Universal
scrambled negative control siRNA (OriGene SR30004) was used as negative control.
For shRNA silencing, a lentiviral vector expressing a short hairpin against HIF1α was
made by cloning the hairpin sequence from pSuper-puro-HIF1a1470 (which was a
kind gift from Daniel Chung, Massachusetts General Hospital, Boston, Massachu-
setts) into the pLVUT vector [29]. A short hairpin sequence against HIF2a was
constructed by cloning the hairpin sequence from pRetro-Super-HIF2a (obtained from
Addgene, Cambridge, MA, USA, number 22100) into the pLVUT vector. A control vector
was made by cloning a hairpin against ﬁreﬂy luciferase into the pLVUT vector. Viral
particles were generated and lentiviral transductions were performed to generate
stable knockdowns as previously described [29]. In summary, lentiviral particles were
harvested in DMEM (hg) medium and stored at −80 °C until further use. Cultured
U87 cells were transduced in 3 consecutive rounds within 8–12 h intervals between
each round with lentiviral supernatant supplemented with polybrene (0.004mg/ml).
Immunohistochemistry
Formalin ﬁxed paraﬃn-embedded 3 μm thick consecutive tissue sections were
mounted on microscope slides and dried overnight at 55 °C. Tissue sections were
deparaﬃnized in xylol and rehydrated in graded series of ethanol, and stained with
hematoxylin and eosin (HE). Antigen retrieval was performed using microwave pre-
treatment in pH 6.0 citrate buffer. Sections were treated with 0.3% H2O2 for 30 min
and blocked for 1 h with 2% BSA to reduce non-speciﬁc primary antibody binding.
Incubation with the following antibodies was performed overnight at 4 °C: rabbit
anti-ZEB1 [1:150, Sigma-Aldrich], rabbit anti-Glut1 [1:100, Abcam], goat anti-YKL40/
GP39 [1:200, Santa Cruz Biotechnology Inc].
As negative controls, primary antibodies were omitted. After incubation with
primary antibodies suitable secondary antibodies conjugated to peroxidase (Dako)
and appropriate tertiary antibodies conjugated to peroxidase (Dako) were used. Stain-
ing was visualized by 3,3′-diaminobenzidine and sections were counterstained with
hematoxylin and mounted. Images of relevant sections were acquired using a C9600
NanoZoomer (Hamamatsu Photonics KK, Hamamatsu City, Japan).
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Statistical analysis
In-vitro data of three independent experiments were represented as the
mean ± standard error of the mean (SEM) in the form of graphs using the GraphPad
Prism version 5.01 (GraphPad for Science, San Diego, CA). Statistical signiﬁcance was
calculated by two way unpaired Student’s t-test unless otherwise mentioned in the
ﬁgure legends. p values < 0.05 were assumed as statistically signiﬁcant for all the
tests.
Results
Hypoxia induces a phenotype shift and increases migration/invasion
in GBM cells
The exposure of U87, SNB75 and U251 cells to hypoxia (1% O2)
for 72 h resulted in a marked difference in their morphology com-
pared to normoxia (20% O2) cultured cells particularly in U87 and
SNB75. Under hypoxic conditions the cells had a more elongated
morphology and were more loosely clustered than normoxia cul-
tured cells (Fig. 1a). The migration/invasion potential of U87 cells
was tested using gelatin-coated transwell inserts. Hypoxia exposed
cells demonstrated almost double the amount of migratory/
invasive cells in comparison to cells cultured under normoxic
conditions (Fig. 1b, c).
Hypoxia promotes mesenchymal transdifferentiation that is
associated with accumulation of nuclear HIF1α, HIF2α and ZEB1
We next explored if the hypoxia-dependent change in morphol-
ogy could be the result of mesenchymal transition in GBM cells.
Therefore the expression of several mesenchymal markers was ex-
amined by immunoﬂuorescencemicroscopy in U87, SNB75 and U251
cells under hypoxic and normoxic conditions. Previously we found
U87 and U251 to represent predominantly the classical (CL)/PN
subtype [28], and SNB75 cells also appeared to be mostly non-
mesenchymal lacking Fibronectin and COL5A1 expression (Fig. 2b).
A strong induction of Fibronectin and COL5A1 expression was seen
under hypoxic conditions in U87 and SNB75 (Fig. 2a, b), whereas
the basal expression levels of YKL40 and Vimentin were not altered
(not shown). In contrast, in U251 cells no such inductions were ob-
served (Fig. 2c) and rather a reduction in migration potential under
Fig. 1. Hypoxia induces a phenotypic shift and enhances the invasive phenotype in GBM cells. (a) Representative Phase contrast microscopic pictures (×10) of U87 and SNB75
cells undergoing phenotypic shift characterized by a more elongated and stretched morphology under hypoxia in comparison to the cells in normoxia; U251 cells appear
less affected by hypoxia. (b) A representative transwell assay showing Coomassie blue stained U87 cells on the insert membranes, demonstrating enhanced invasive ca-
pacity under hypoxic conditions in comparison to cells under normoxia. 0.1% FCS containing media was used as the control and 10% FCS served as the chemo-attractant. (c)
Quantiﬁed data of the invasion assay are depicted as mean of three independent experiments measured in triplicate ± SEM (**p < 0.01).
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hypoxic conditions was observed in wound-healing assays
(Supplementary Fig. S1a, b).
To explore the underlying mechanism of the hypoxia-induced
mesenchymal shift we employed U87 cells and performed western
blot analyses to evaluate the expression levels of HIF1α and HIF2α
along with EMT inducing transcription factors such as Snail1, Snail2/
Slug, ZEB1 and TWIST, and Fibronectin and COL5A1. The expression
of both HIF1α and HIF2α was strongly induced together with the
mesenchymal markers Fibronectin and COL5A1, and out of the tran-
scription factors tested we could detect only ZEB1 to be signiﬁcantly
upregulated under hypoxia (Fig. 2d). Of note, we detected the
124 kDa form of ZEB1 and not the larger ~200 kDa form, which are
both known to be speciﬁc for ZEB1 [30]. Further, immunoﬂuores-
cence analysis revealed nuclear localization of HIF1α, HIF2α and ZEB1
in U87 cells under hypoxic conditions, while under normoxia little
or no nuclear expression of these transcription factors was de-
tected (Fig. 2e). Of note U251 cells that did not demonstrate a
hypoxia-induced gain in mesenchymal marker expression showed
nuclear translocation of HIF1α, but not of ZEB1 (Supplementary
Fig. S1c, d). Time course experiments showed accumulation of HIF1α,
HIF2α and ZEB1 after 6 and 12 h hypoxia exposure and mesenchy-
mal differentiation became evident after 48 h exposure as indicated
by the appearance of Fibronectin expression (Supplementary Fig. S2).
Thus, these results suggested the involvement of HIF1α, HIF2α and
ZEB1 in inducing a mesenchymal shift.
Digoxin effectively inhibits the hypoxia-induced mesenchymal shift
and increase in invasion
To investigate further the role of HIFs in the hypoxia-inducedmes-
enchymal shift, we employed a cardiac glycoside, digoxin, a well-
known inhibitor of HIF1α and HIF2α. Digoxin is known to have
modest effects on global protein synthesis but is a very potent in-
hibitor of HIF1α mRNA translation [31]. Different concentrations of
digoxin were tested in hypoxia-exposed U87 cells to examine which
dose was effective in blocking the phenotypic shift. A concentra-
tion of 150 nM appeared effective and was also able to inhibit the
accumulation of HIF1α and Fibronectin at the protein level
Fig. 2. Hypoxia induces a mesenchymal shift in GBM. (a–c) Immunoﬂuorescence analysis for mesenchymal markers (Fibronectin and COL5A1) in U87, SNB75 and U251
cells exposed to hypoxia in comparison to these cells grown under normoxic conditions; images obtained at ×20 magniﬁcation. (d) Western blots showing the expression
levels of multiple markers associated with a mesenchymal phenotype in U87 cells under hypoxia conditions. (e) Immunoﬂuorescence analysis revealing nuclear localiza-
tion of HIF1α, HIF2α and ZEB1 in U87 cells exposed to hypoxia; images obtained at ×40 magniﬁcation.
110 J.V. Joseph et al./Cancer Letters 359 (2015) 107–116
(Supplementary Fig. S3a, b). Higher concentrations of digoxin ap-
peared toxic to the cells. Digoxin added 2 h prior to placing the cells
under hypoxia effectively prevented the phenotypic shift andwestern
blot analysis further revealed that digoxin also prevented largely
the induction of HIF1α and HIF2α together with that of ZEB1,
Fibronectin and COL5A1 (Fig. 3a, b). Next we examined the effect
of digoxin on the hypoxia-dependent increase of migration/
invasion in U87 cells; a signiﬁcant reduction (~2 fold) in the invasive
potential of these cells was seen (Fig. 3c, d), indicating essential roles
of HIF1α and/or HIF2α in mesenchymal differentiation and en-
hanced invasive potential.
HIF1α is instrumental for the induction of ZEB1, a mesenchymal shift
and increased migration/invasion under hypoxia
We proceeded by examining which of the two HIFs are instru-
mental for inducing a mesenchymal shift. U87 cells were generated
in which either HIF1α or HIF2α expression was stably silenced using
selective shRNAs and control scrambled shRNA encoded by lentiviral
vectors. Effective knockdown was conﬁrmed at the protein level by
western blotting and we found that the silencing of HIF1α and not
HIF2α effectively prevented the induction of ZEB1 and Fibronectin
expression under hypoxia (Fig. 4a). In line with this, control and
HIF2α knockdown cells showed the characteristic shift in morphol-
ogy upon hypoxia, whereas HIF1α knockdown cells appeared similar
to normoxia cultured U87 cells (Fig. 4b). The HIF1α knockdown cells
also showed a clear decline in the invasive potential in compari-
son to the HIF2α knockdown and control cells under hypoxic
conditions (Fig. 4c, d).
ZEB1 mediates the hypoxia-induced mesenchymal shift and
invasive phenotype
To further examine the role of ZEB1 we silenced the expres-
sion of ZEB1 with 2 different speciﬁc siRNAs in comparison to
scrambled siRNAs. Exposure of siZEB1-I and -II-transfected U87 cells
to hypoxia prevented the phenotypic shift while the control
cells (mock and the scrambled siRNA treated) showed a visible
Fig. 3. Digoxin prevents the hypoxia-induced mesenchymal shift and elevated invasion. (a) Representative phase contrast microscopic pictures (×10 magniﬁcation) showing
the effect of hypoxia on the morphology of U87 cells in the presence and absence of digoxin. (b) Western blots showing the effect of digoxin on the expression of the in-
dicated proteins in hypoxia exposed U87 cells. (c) A representative transwell assay showing Coomassie blue stained U87 cells on the membrane inserts and quantiﬁed results
are depicted in (d). The bars represent the mean of in general three independent experiments measured in triplicate ± SEM (**p < 0.01, DMSO vs digoxin for 0.1% FCS and
##p < 0.01 DMSO vs digoxin for 10% FCS).
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morphological shift under hypoxia (Fig. 5a). Western blotting con-
ﬁrmed inhibition of ZEB1 induction by hypoxia in the speciﬁc ZEB1
siRNA transfected U87 cells together with an absence of Fibronectin
and COL5A1 accumulation (Fig. 5b). In ZEB1 knockdown cells HIF1α
induction remained as strong as in control cells indicating that HIF1α
acts upstream of ZEB1 in triggering a mesenchymal shift under
hypoxia (Fig. 5b). Signiﬁcant reduction in the invasive potential was
also observed in U87 cells under hypoxia following the silencing
of ZEB1 (Fig. 5c, d). This indicates that ZEB1 is a crucial mediator
of the hypoxia-induced HIF1α dependent mesenchymal shift and
the invasive phenotype of these GBM cells.
Overlapping GLUT1, ZEB1 and YKL40 expression in patient material
Finally, in order to examine whether hypoxia-induced mesen-
chymal transitionmay also be relevant in patient tumors, we selected
GBM patient material showing multiple pseudopalisading ne-
crotic regions as was determined by H&E staining (Fig. 6a).
Subsequently, we performed immunohistochemical staining on serial
sections made from this material for GLUT1, a hypoxia marker, ZEB1
and the mesenchymal marker YKL40. Interestingly, we noticed an
overlapping expression of these markers in the hypercellular zones/
pseudopalisades surrounding the necrotic foci (Fig. 6b). Taken
Fig. 4. HIF1α knockdown prevents hypoxia-induced mesenchymal transition. (a) Western blot analyses showing effective downregulation of HIF1α and HIF2α in U87 cells
following ShRNA-mediated gene silencing and exposure to hypoxia when compared to control scramble shRNA (shSCR). The effects on ZEB1 and Fibronectin expression
were also examined. (b) Representative phase contrast microscopic pictures (×10 magniﬁcation) of U87 cells transfected with shHIF2α or shSCR undergoing a phenotypic
shift under hypoxia, whereas U87-ShHIF1α cells largely retained their original morphology under hypoxic conditions. (c) Representative pictures of transwell assays showing
Coomassie blue stained U87 (shSCR, shHIF1α, shHIF2α) cells on the membrane inserts. A decreased invasive potential of HIF1α knockdown cells under hypoxia was seen.
0.1% FCS containing media was used as the control and 10% FCS served as the chemo-attractant. Quantiﬁed data for invading cells/ﬁeld are shown in (d) as mean ± SEM of
3 independent experiments (**p < 0.01 and ***p < 0.001).
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together this provides further evidence for a link between hypoxia
and ZEB1-mediated mesenchymal transition in GBM.
Discussion
Hypoxic regions are frequently found in GBM and the presence
of extensive hypoxic areas has been associated with worse prog-
nosis in GBM patients, which has been linked to hypoxic cancer cells
displaying a more malignant phenotype and being more resistant
to chemotherapy and radiation [32–34]. The HIF transcription factors
are instrumental for orchestrating adaptive responses to cope with
oxygen shortage, and particularly HIF1α is key in inducing expres-
sion of glycolytic enzymes and several angiogenic growth factors
[12,17,35]. HIF1α was found to be upregulated in many of the ma-
lignant tumors primarily by hypoxia-mediated protein stabilization
[12].
In GBM, HIF1α seems to be primarily localized to the
pseudopalisading cells around necrotic cores and to tumor cells at
the invasive edge of the tumor that inﬁltrate the normal brain tissue
[36]. Extensive necrosis and elevated levels of HIF-regulated genes
are features that were more frequently found in mesenchymal GBM
when compared to proneural GBM [4,6,37]. Despite the associa-
tion between hypoxia and mesenchymal GBM, the potential
molecular mediators that induce amesenchymal shift under hypoxic
condition remain a poorly studied area.
In the present study we showed that hypoxia is a strong inducer
of a mesenchymal shift in GBM that was associated with morpho-
logical changes, upregulation of known mesenchymal markers like
Fibronectin and COL5A1 and elevated invasive potential in vitro. We
independently tested the role of the two HIFα proteins – HIF1α and
HIF2α, as we observed the up-regulation and nuclear transloca-
tion of both of these HIF proteins under hypoxic conditions. HIF1α
is the most well studied member of the HIFα family due to its uni-
versal pattern of expression, unlike HIF2α that shows a more
restricted expression pattern. Notably, HIF2α has been reported to
play a crucial role in regulating stemness in GBM [38–40]. We found
that hypoxia-induced HIF1α, and not HIF2α, is a key mediator for
mesenchymal transition. The EMT transcription factor ZEB1 known
to regulate EMT in epithelial cancers [41,42] appeared instrumen-
tal in this transition since siRNA-dependent silencing of ZEB1
Fig. 5. ZEB1 silencing effectively prevents the hypoxia-induced mesenchymal shift and invasion. (a) siRNA silencing of ZEB1 effectively prevented the hypoxia-induced phe-
notypic shift in U87 cells in comparison to the Mock and Si-negative control treated cells; representative phase contrast microscopic pictures (×10) are shown. (b) Western
blot analysis showing downregulation of ZEB1 following siRNA administration; levels of HIF1α, Fibronectin and COL5A1 are also shown. (c) A representative Transwell assay
showing Coomassie blue stained U87 cells on the membrane inserts, demonstrating decreased invasive potential under hypoxia following silencing of ZEB1 expression in
comparison to the Mock and negative siRNA treated cells. Quantiﬁcation of invading cells is shown in (d) where bars indicate the average invading cells/ﬁeld in 3 indepen-
dent experiments ± SEM. (****p < 0.0001 between ZEB1 targeted siRNA-treated cells vs scrambled siRNA).
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prevented the hypoxia induced mesenchymal shift and enhanced
invasive capacity. Our ﬁnding of overlapping ZEB1, GLUT1 and YKL40
expression patterns surrounding necrotic areas in GBM patient ma-
terial provides evidence for the occurrence of local hypoxia-
induced ZEB1-mediated mesenchymal transition in these tumors.
Interestingly, ZEB1 has been recently associated with invasive be-
havior, temozolomide resistance and stemness in GBM [43].
Moreover, we previously identiﬁed a critical role for ZEB1 in me-
diating a TGF-β-induced mesenchymal shift in GBM cells [28].
Furthermore, the TNFα/NF-κB and WNT/β-catenin pathways were
also reported to be able to mediate a mesenchymal shift in GBM
[44,45]. Of note, hypoxia did not trigger amesenchymal shift in U251
cells, whereas previously we found that these cells underwent such
transdifferentiation upon TGF-β exposure [28]. Apparently, some
GBM cells are refractory to one mesenchymal-inducing stimulus
while being sensitive to others providing multiple ways for GBM
cell to acquire the aggressive mesenchymal status. The mesenchy-
mal phenotype in GBM, in addition to being regulated by the
transcription factors C/EBP-β, STAT3 and TAZ [6,46], is thus con-
trolled by various external stimuli. How and whether these
mechanisms are further interlinked remains to be investigated.
In summary, as indicated in (Fig. 7) hypoxia induces a mesen-
chymal shift in GBM that is mediated by the HIF1α–ZEB1 axis leading
to an elevated invasive potential. Our results further indicate the
crucial role of micro-environmental factors like hypoxia in deﬁn-
ing GBM sub-types and thus the boundaries between thesemolecular
subtypes appear less strict than initially believed. Hence, thera-
peutic targeting of HIF1α or its downstream target ZEB1 might
provide a possible strategy for improving the prognoses for GBM
patients.
Fig. 6. Local/regional mesenchymal transition detected in hypoxic zones in GBM patient material. (a) Photomicrograph of hematoxylin–eosin (H&E) staining [original mag-
niﬁcation ×4] in GBM patient material showing pseudopalisading necrosis characterized by a garland-like arrangement of hypercellular tumor nuclei (arrows) lining up
around irregular foci of tumor necrosis. (b) Immunohistochemical staining for GLUT1, ZEB1 and YKL40 in consecutive sections detects overlapping expression patterns of
these markers in pseudopalisading cells [original magniﬁcation ×100]. The areas indicated with boxes are enlarged. *Indicates necrotic region.
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